Predictability of insulin initiation could have been significantly improved if baseline information were available on the symptoms of hyperglycemia, weight loss, metabolic decompensation and ketosis, time course and severity of hyperglycemic symptoms, comorbidities, cardiovascular disease, microvascular complications, dementia, mental disorders, and various results of blood tests, such as C-peptide and glutamic acid decarboxylase antibody. This evidence concerns the gene INS and cardiovascular disorder.